Although dasatinib is more effective for cancer cells with aberrant Src activation (Zhang and Yu, 2012), no Src inhibitors successfully suppresses tumors in cancer patients when used alone, possibly because there is no suitable biomarker to monitor Src activation in tumor tissues or because the treatment triggers alternative routes for resistance to Src inhibition (Zhang and Yu, 2012). Here, SRC is linked to cancer.